ReviewClujul medical (1957)2016
Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies.
Review in Clujul medical (1957), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Past, Present, and Future Therapies for Alcohol-associated Hepatitis.Clinical therapeutics · 2023Pooled it
- Influence of cytokines, circulating markers and growth factors on liver regeneration and post-hepatectomy liver failure: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis.Scientific reports · 2020Pooled it
- Non-Invasive Biomarkers for Assessing Liver Fibrosis in Biliary Atresia: A Literature Review.International journal of molecular sciences · 2026Review
- Hyaluronan and Associated Biomarkers: A Longitudinal Cohort Study in Patients with Obesity Following Gastric Bypass Surgery.Obesity surgery · 2026Article
- Translational framework linking perfluoroheptanoic acid (PFHpA) exposure to metabolic dysfunction associated steatotic liver disease in adolescents.Communications medicine · 2025Article
- Characterization of liver, adipose, and fecal microbiome in obese patients with MASLD: links with disease severity and metabolic dysfunction parameters.Microbiome · 2025Article
- Inverted Pyramid Nanostructures Coupled with a Sandwich Immunoassay for SERS Biomarker Detection.Nanomaterials (Basel, Switzerland) · 2025Article
- Glisson's capsule matrix structure and function is altered in patients with cirrhosis irrespective of aetiology.JHEP reports : innovation in hepatology · 2023Article
- A salivary biomarker panel to detect liver cirrhosis.iScience · 2023Article
- A standardized pomegranate fruit extract ameliorates thioacetamide-induced liver fibrosis in rats via AGE-RAGE-ROS signaling.Heliyon · 2023Article
- Serum 25-hydroxyvitamin D and hyaluronic acid levels as markers of fibrosis in patients with chronic liver disease at the main tertiary referral hospital in Ghana: A case-control study design.Health science reports · 2023Article
- Clinical importance of laboratory biomarkers in liver fibrosis.Biochemia medica · 2022Review
- Role of serum hyaluronic acid in predicting necroinflammatory activity of the nonalcoholic fatty liver disease.Hepatology forum · 2022Article
- Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients.Clinical and experimental hepatology · 2021Article
- Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.Advanced drug delivery reviews · 2021Review
- Type IV Collagen 7s Reflects Central Venous Pressure and Right Ventricular End-Diastolic Pressure in Patients with Congenital Heart Disease After Biventricular Repair.Pediatric cardiology · 2021Article
- Content of the Major Extracellular Matrix Components of the Liver and Lungs in Mice with Chronic BCG-Granulomatosis Treated with Liposome-Encapsulated Dextrazide.Bulletin of experimental biology and medicine · 2021Article
- Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study.Current therapeutic research, clinical and experimental · 2021Article
- Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD.International journal of environmental research and public health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic liver diseases represent a significant public health problem worldwide. The degree of liver fibrosis secondary to these diseases is important, because it is the main predictor of their evolution and prognosis. Hyaluronic acid is studied as a non-invasive marker of liver fibrosis in chronic liver diseases, in an attempt to avoid the complications of liver puncture biopsy, considered the gold standard in the evaluation of fibrosis. We review the advantages and limitations of hyaluronc acid, a biomarker, used to manage patients with chronic viral hepatitis B or C infection, non-alcoholic fatty liver disease, HIV-HCV coinfection, alcoholic liver disease, primary biliary cirrhosis, biliary atresia, hereditary hemochromatosis and cystic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.